Transaction adds CRISPR-based precision microbiome technology and BiomElix® One, a poultry feed additive approved in Brazil

交易增加了基于CRISPR的精准微生物组技术和BiomElix® One，这是一种在巴西获批的家禽饲料添加剂

INDIANAPOLIS

印第安纳波利斯

,

，

Aug. 25, 2026

2026年8月25日

/PRNewswire/ -- BiomEdit, a pioneering animal health biotechnology company, today announced it has acquired Folium Science's technology platform and pipeline assets, including BiomElix® One, a poultry feed additive approved in Brazil. The transaction adds both an approved product asset and a complementary CRISPR-based microbiome technology to BiomEdit's existing capabilities and broadens the company's pipeline across animal health and nutrition..

/美通社/ -- 领先的动物健康生物技术公司 BiomEdit 今日宣布，已收购 Folium Science 的技术平台及管线资产，其中包括在巴西获批的家禽饲料添加剂 BiomElix® One。此次交易为 BiomEdit 现有能力增添了一项已获批的产品资产以及一项互补的基于 CRISPR 的微生物组技术，并拓宽了公司在动物健康与营养领域的产品管线。

Continue Reading

继续阅读

BiomEdit Acquires Folium Science Technology and Pipeline Assets

BiomEdit 收购 Folium Science 的技术及管线资产

BiomEdit is pioneering a new class of genetically engineered bacterial biologics called Programmable Veterinary Biologics™, designed to perform targeted biological functions in animals. This acquisition adds Folium's Guided Biotics® CRISPR-Cas technology, a complementary approach designed to selectively target specific bacterial populations within the microbiome while preserving the broader microbial community..

BiomEdit 正在开创一类名为“可编程兽医生物制品™”的新型基因工程细菌生物药，旨在动物体内执行靶向生物学功能。此次收购引入了 Folium 的 Guided Biotics® CRISPR-Cas 技术，这是一种互补性方法，旨在选择性靶向微生物组内的特定细菌种群，同时保护更广泛的微生物群落。

'Folium assembled an exceptional scientific team and built a differentiated platform that complements BiomEdit's existing technology,' said Aaron Schacht, CEO of BiomEdit. 'One approach engineers beneficial bacteria to perform targeted biological functions; the other selectively targets specific bacterial populations within the microbiome.

“Folium组建了一支卓越的科学家团队，并打造了一个与BiomEdit现有技术形成互补的差异化平台。”BiomEdit首席执行官Aaron Schacht表示。“一种方法是对有益细菌进行工程化改造，使其执行靶向生物学功能；另一种方法则选择性地靶向微生物组内的特定细菌种群。

Together, these scientific approaches give us a broader set of tools to address important animal health and production challenges.'.

这些科学方法共同为我们提供了更广泛的工具，以应对动物健康和生产方面的重要挑战。

BiomEdit will now have two advanced poultry product programs based on distinct precision microbiome technologies. The company's lead candidate, BE-101, is being developed for the prevention of mortality associated with necrotic enteritis in broiler chickens and is in the final stages of the conditional licensure process with the U.S.

BiomEdit 现在将拥有两个基于独特精准微生物组技术的先进家禽产品项目。该公司的主要候选产品 BE-101 正在开发中，用于预防肉鸡坏死性肠炎相关的死亡，目前正处于美国有条件许可流程的最后阶段。

Department of Agriculture's Center for Veterinary Biologics (USDA CVB). Folium's BiomElix® One has received approval from Brazil's Ministry of Agriculture and Livestock (MAPA) for use as an animal feed additive..

美国农业部兽医生物制品中心（USDA CVB）。Folium公司的BiomElix® One已获得巴西农业和畜牧业部（MAPA）批准，用作动物饲料添加剂。

'I'm proud of what our team built and confident that, in BiomEdit, our science has found the right home: one with the vision, expertise and development capability to realize its full potential for animal health,' said Ed Fuchs, co-founder of Folium Science.

“我为我们团队所打造的成果感到自豪，并坚信我们的科学在 BiomEdit 找到了理想的归属：一个拥有实现动物健康领域全部潜力所需的愿景、专业知识和开发能力的平台。”Folium Science 联合创始人 Ed Fuchs 表示。

'Ed Fuchs, Martin Woodward and the entire Folium team have built a strong foundation over the past decade,' said Schacht. 'By combining these complementary technologies in one platform, we can both engineer beneficial microbes to perform specific biological functions and selectively reshape microbial communities.

“Ed Fuchs、Martin Woodward 以及整个 Folium 团队在过去十年中奠定了坚实的基础，”Schacht 表示。“通过将这些互补技术整合到一个平台中，我们既能设计有益微生物以执行特定的生物功能，又能选择性地重塑微生物群落。

This broader toolkit expands our ability to design precise, differentiated solutions that improve animal health and productivity.'.

这一更广泛的工具包增强了我们设计精准、差异化解决方案的能力，从而提升动物健康水平和生产性能。

Terms of the transaction were not disclosed.

交易条款未予披露。

About BiomEdit

关于 BiomEdit

BiomEdit is pioneering Programmable Veterinary Biologics™, a new class of engineered microbial strains that target specific biological activity addressing key challenges in livestock and pets. The company is advancing programs in infectious disease, chronic disease and sustainability. Founded in 2022, BiomEdit is backed by leading investors including Anterra Capital, Viking Global Investors, Nutreco, AgriZeroNZ, Elevate Ventures, Betagro Ventures and others.

BiomEdit 正在开创“可编程兽医生物制品™”这一全新领域，这是一类经过工程化改造的微生物菌株，旨在通过特定的生物活性解决畜牧业和宠物健康中的关键挑战。公司正积极推进针对传染病、慢性病以及可持续发展的相关项目。BiomEdit 成立于 2022 年，获得了包括 Anterra Capital、Viking Global Investors、Nutreco、AgriZeroNZ、Elevate Ventures、Betagro Ventures 等在内的领先投资机构的支持。

.

。

Biomedit.com

Biomedit.com

Media Contact:

媒体联系人：

Julie Lawless

朱莉·劳勒斯

[email protected]

[email protected]

+1 615-585-5861

+1 615-585-5861

SOURCE BiomEdit

来源 BiomEdit

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示